Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026
Company Drug

Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study

Fineline Cube Feb 20, 2025

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clearance from the National Medical...

Company Medical Device

Huadong Medicine’s MediBeacon TGFR System Approved by NMPA for GFR Measurement

Fineline Cube Feb 20, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received marketing approval from...

Company Deals

Sunshine Guojian and Shenyang 3SBio License 612 and 708 Programs for Anti-Tumor Development

Fineline Cube Feb 20, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd and Shenyang 3SBio Co., Ltd, both subsidiaries of...

Company

Antengene to Boost T Cell Engager Platform with AI Investment and DeepSeek Deployment

Fineline Cube Feb 20, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced plans to increase investment in establishing a...

Company Deals

Jiangxi Rimag Group and Xunfei Healthcare Form Strategic Alliance for Smart Healthcare

Fineline Cube Feb 20, 2025

China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced a strategic alliance with Xunfei Healthcare...

Company Deals

Rendu Biotechnology Partners with Green Apple Medical System for RNA Diagnostics Expansion

Fineline Cube Feb 20, 2025

Rendu Biotechnology Co., Ltd., (SHA: 688193) a Shanghai-based specialist in RNA molecular diagnostics, has entered...

Company Deals

Genuine Biotech Files for Hong Kong IPO with Azvudine and ZS-1003 in Pipeline

Fineline Cube Feb 20, 2025

China-based Genuine Biotech Limited has filed for an initial public offering (IPO) on the Hong...

Company Legal / IP

AstraZeneca Faces Class Action Lawsuits Over China Legal Issues

Fineline Cube Feb 20, 2025

AstraZeneca plc (AZ, NASDAQ: AZN) is facing multiple class action lawsuits in the United States...

Company Deals Drug

Biogen Licenses Stoke Therapeutics’ Zorevunersen for Dravet Syndrome Outside Americas

Fineline Cube Feb 19, 2025

US-based Biogen Inc. (NASDAQ: BIIB) has entered into a licensing agreement with Stoke Therapeutics, Inc....

Company Drug

TAHO Pharma’s TAH3311 Oral Film Shows Bioequivalence to Eliquis in Study

Fineline Cube Feb 19, 2025

Taiwan-based TAHO Pharmaceuticals announced positive preliminary results from a pivotal study for its TAH3311 oral...

Company Drug

Sanofi’s Dupixent Receives Priority Review from FDA for Bullous Pemphigoid Treatment

Fineline Cube Feb 19, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) announced that the US Food and Drug Administration (FDA) has...

Company Deals

CSPC Pharma Licenses SYS 6005 to Radiance Biopharma for Global Markets

Fineline Cube Feb 19, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced a licensing agreement with Radiance Biopharma, Inc.,...

Company Drug

Biokin Pharmaceutical’s BL-M07D1 Receives NMPA Approval for Phase II/III Study in HER2+ Breast Cancer

Fineline Cube Feb 19, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...

Company Drug

Gilead Sciences’ Lenacapavir NDA for HIV Prevention Accepted by FDA for Priority Review

Fineline Cube Feb 19, 2025

US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that the New Drug Application (NDA) for its...

Company Drug

Merck’s Welireg Wins Conditional EU Approval for VHL Disease and Advanced RCC

Fineline Cube Feb 19, 2025

US pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that it has received...

Company

GSK and Abbott Announce Leadership Changes in Key Roles

Fineline Cube Feb 19, 2025

Recent days have seen significant leadership changes at two pharmaceutical giants: UK-based GSK plc (LON:...

Company

Medtronic Q3 Earnings Show 4.1% Organic Growth, Driven by Cardiac Ablation

Fineline Cube Feb 19, 2025

US-Irish medical device company Medtronic (NYSE: MDT) reported financial results for the third quarter (Q3)...

Company Deals

QuantumPharm and Hengjian Launch GBA AI+ Innovation Consortium

Fineline Cube Feb 19, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., and Guangdong Hengjian Investment Holding...

Company

Deepwise Information Integrates DeepSeek into Medical Data Platform

Fineline Cube Feb 19, 2025

Deepwise Information, a leading artificial intelligence company in the medical field, has fully integrated its...

Company

Weimai Qingtong Medical Technology Completes Tens of Millions Yuan B+ Round

Fineline Cube Feb 19, 2025

Weimai Qingtong Medical Technology (WEMT), a medical device company based in Wuxi, has completed a...

Posts pagination

1 … 166 167 168 … 621

Recent updates

  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
  • Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
  • Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
  • Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
  • Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.